New long‐standing metabolites of 17α‐methyltestosterone are detected in HepG2 cell in vitro metabolic model and in human urine
Drug Testing and Analysis · 2024
DOI: 10.1002/dta.3589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2024. Verfasst von Yiannis S Angelis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece. Hauptthemen laut MEDLINE: Methyltestosterone, Gas Chromatography-Mass Spectrometry, Substance Abuse Detection, Doping in Sports. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Novel metabolites of the anabolic androgenic steroid 17α‐methyltestosterone have been detected in HepG2 cell in vitro metabolic model and in human urine. Their detection was accomplished through targeted gas chromatography–(tandem) mass spectrometry analysis that has been based on microscale synthesized standards. The related synthesis and the gas chromatography–(tandem) mass spectrometry characterization of the analytical standards are described. All newly presented metabolites have a fully reduced steroid A‐ring with either an 17,17‐dimethyl‐18‐nor‐Δ13 structure or they have been further oxidized at position 16 of the steroid backbone. Metabolites with 17,17‐dimethyl‐18‐nor‐Δ13 structure may be considered as side products of phase II metabolic sulfation of the 17β‐hydroxy group of methyltestosterone or its reduced tetrahydro‐methyltestosterone metabolites 17α‐methyl‐5β‐androstane‐3α,17β‐diol and 17α‐methyl‐5α‐androstane‐3α,17β‐diol that produce the known epimeric 17β‐methyl‐5β‐androstane‐3α,17α‐diol and 17β‐methyl‐5α‐androstane‐3α,17α‐diol metabolites. The prospective of these new metabolites to increase detection time windows and improve identification was investigated by applying the World Anti‐doping Agency TD2021IDCR criteria. The new metabolites, presented herein, complement the current knowledge on the 17α‐methyltestosterone metabolism and in some cases can be used as additional long‐term markers in the frame of sport doping drug testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece.
- Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
- Laboratory of Cell Proliferation and Ageing, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece.
ORCID-Profile: Yiannis S Angelis
Zitieren
APA
Angelis, Y. S., Sakellariou, P., Fragkaki, A. G., Karnava, S., Goula, O., Kiousi, P., Kioukia-Fougia, N., Georgakopoulos, C., Loui, S., Chlapana, F., & Kletsas, D. (2024). New long‐standing metabolites of 17α‐methyltestosterone are detected in HepG2 cell in vitro metabolic model and in human urine. Drug Testing and Analysis. https://doi.org/10.1002/dta.3589
Vancouver
Angelis YS, Sakellariou P, Fragkaki AG, Karnava S, Goula O, Kiousi P, et al. New long‐standing metabolites of 17α‐methyltestosterone are detected in HepG2 cell in vitro metabolic model and in human urine. Drug Testing and Analysis. 2024. doi:10.1002/dta.3589
BibTeX
@article{Angelis2024,
author = {Angelis, Yiannis S and Sakellariou, Panagiotis and Fragkaki, Argyro G and Karnava, Sophia and Goula, Olga and Kiousi, Polyxeni and Kioukia-Fougia, Nassia and Georgakopoulos, Costas and Loui, Stella and Chlapana, Fotini and Kletsas, Dimitris},
title = {New long‐standing metabolites of 17α‐methyltestosterone are detected in HepG2 cell in vitro metabolic model and in human urine},
journal = {Drug Testing and Analysis},
year = {2024},
doi = {10.1002/dta.3589}
}
EUVIMED